Steward Partners Investment Advisory, LLC Bei Gene, Ltd. Transaction History

Steward Partners Investment Advisory, LLC

  • $11 Billion
  • Q4 2024

A detailed history of Steward Partners Investment Advisory, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 707 shares of BGNE stock, worth $160,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
707
Previous 699 1.14%
Holding current value
$160,283
Previous $156,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025
BUY
$174.72 - $246.04 $1,397 - $1,968
8 Added 1.14%
707 $130,000
Q3 2024

Nov 14, 2024
SELL
$143.93 - $224.51 $719 - $1,122
-5 Reduced 0.71%
699 $156,000
Q2 2024

Aug 08, 2024
BUY
$129.52 - $174.32 $1,554 - $2,091
12 Added 1.73%
704 $100,000
Q1 2024

May 15, 2024
SELL
$141.8 - $181.47 $283 - $362
-2 Reduced 0.29%
692 $108,000
Q4 2023

Feb 12, 2024
BUY
$158.67 - $201.58 $46,648 - $59,264
294 Added 73.5%
694 $125,000
Q2 2022

Aug 04, 2022
BUY
$121.11 - $216.05 $48,444 - $86,420
400 New
400 $65,000
Q2 2021

Aug 13, 2021
SELL
$292.75 - $367.01 $117,100 - $146,804
-400 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$260.64 - $382.12 $104,256 - $152,848
400 New
400 $139,000
Q3 2020

Oct 30, 2020
SELL
$189.18 - $286.44 $378 - $572
-2 Closed
0 $0
Q2 2020

Aug 06, 2020
BUY
$123.9 - $195.41 $247 - $390
2 New
2 $0
Q3 2018

Oct 23, 2018
SELL
$152.62 - $189.66 $8,241 - $10,241
-54 Closed
0 $0
Q2 2018

Jul 20, 2018
BUY
$152.5 - $216.77 $8,235 - $11,705
54 New
54 $8,000

Others Institutions Holding BGNE

# of Institutions
254
Shares Held
42.4M
Call Options Held
135K
Put Options Held
111K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email